(Circulation. 1996;94:2021-2038.)
© 1996 American Heart Association, Inc.
Articles |
Clinical Approach to Genetic Cardiomyopathy in Children
the Department of Cardiology (M.L.S., R.V.L., S.E.L.), Division of Genetics, Inborn Errors of Metabolism Service, Department of Medicine (G.F.C., M.S.K.), and Department of Pathology (A.P.-A.), Children's Hospital, Boston, Mass; and Department of Pediatrics (M.L.S., G.F.C., M.S.K., R.V.L., S.E.L.) and Department of Pathology (A.P.-A.), Harvard Medical School, Boston, Mass.
Correspondence to Steven E. Lipshultz, MD, Department of Cardiology, Children's Hospital, 300 Longwood Ave, Boston, MA 02115. E-mail Lipshultz@A1.TCH.Harvard.edu.
Background Cardiomyopathy (CM) remains one of the leading cardiac causes of death in children, although in the majority of cases, the cause is unknown. To have an impact on morbidity and mortality, attention must shift to etiology-specific treatments. The diagnostic evaluation of children with CM of genetic origin is complicated by the large number of rare genetic causes, the broad range of clinical presentations, and the array of specialized diagnostic tests and biochemical assays.
Methods and Results We present a multidisciplinary diagnostic approach to pediatric CM of genetic etiology. We specify criteria for abnormal left ventricular systolic performance and structure that suggest CM based on established normal echocardiographic measurements and list other indications to consider an evaluation for CM. We provide a differential diagnosis of genetic conditions associated with CM, classified as inborn errors of metabolism, malformation syndromes, neuromuscular diseases, and familial isolated CM disorders. A diagnostic strategy is offered that is based on the clinical presentation: biochemical abnormalities, encephalopathy, dysmorphic features or multiple malformations, neuromuscular disease, apparently isolated CM, and pathological specimen findings. Adjunctive treatment measures are recommended for severely ill patients in whom a metabolic cause of CM is suspected. A protocol is provided for the evaluation of moribund patients.
Conclusions In summary, we hope to assist pediatric cardiologists and other subspecialists in the evaluation of children with CM for a possible genetic cause using a presentation-based approach. This should increase the percentage of children with CM for whom a diagnosis can be established, with important implications for treatment, prognosis, and genetic counseling.
Key Words: diagnosis • genetics • cardiomyopathy
This article has been cited by other articles:
 |
|
 |
|
  J. P. Kaski, P. Syrris, M. T. T. Esteban, S. Jenkins, A. Pantazis, J. E. Deanfield, W. J. McKenna, and P. M. Elliott Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy Circ Cardiovasc Genet, October 1, 2009; 2(5): 436 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Gollob Modulating Phenotypic Expression of the PRKAG2 Cardiac Syndrome Circulation, January 15, 2008; 117(2): 134 - 135. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Colan, S. E. Lipshultz, A. M. Lowe, L. A. Sleeper, J. Messere, G. F. Cox, P. R. Lurie, E. J. Orav, and J. A. Towbin Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry Circulation, February 13, 2007; 115(6): 773 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Cox, L. A. Sleeper, A. M. Lowe, J. A. Towbin, S. D. Colan, E. J. Orav, P. R. Lurie, J. E. Messere, J. D. Wilkinson, and S. E. Lipshultz Factors Associated With Establishing a Causal Diagnosis for Children With Cardiomyopathy Pediatrics, October 1, 2006; 118(4): 1519 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Tsirka, K. Trinkaus, S.-C. Chen, S. E. Lipshultz, J. A. Towbin, S. D. Colan, V. Exil, A. W. Strauss, and C. E. Canter Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation J. Am. Coll. Cardiol., July 21, 2004; 44(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz, L. A. Sleeper, J. A. Towbin, A. M. Lowe, E. J. Orav, G. F. Cox, P. R. Lurie, K. L. McCoy, M. A. McDonald, J. E. Messere, et al. The Incidence of Pediatric Cardiomyopathy in Two Regions of the United States N. Engl. J. Med., April 24, 2003; 348(17): 1647 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Doevendans Genetic Polymorphisms and Cardiac Failure Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 23 - 29. [PDF]
|
|
|
|
 |
|
 J R L. HAMILTON and A. HASAN Cardiopulmonary transplantation in children: a reason for optimism? Heart, December 1, 2001; 86(6): 607 - 608. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Lipshultz, K. A. Easley, E. J. Orav, S. Kaplan, T. J. Starc, J. T. Bricker, W. W. Lai, D. S. Moodie, G. Sopko, K. McIntosh, et al. Absence of Cardiac Toxicity of Zidovudine in Infants N. Engl. J. Med., September 14, 2000; 343(11): 759 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Rosenthal Cardiomyopathy in Infants: A Brief Overview NeoReviews, August 1, 2000; 1(8): e139 - 145. [Full Text]
|
|
|
|
|
|
E. Helton, R. Darragh, P. Francis, F. J. Fricker, K. Jue, G. Koch, D. Mair, M. E. Pierpont, J. V. Prochazka, L. S. Linn, et al. Metabolic Aspects of Myocardial Disease and a Role for L-Carnitine in the Treatment of Childhood Cardiomyopathy Pediatrics, June 1, 2000; 105(6): 1260 - 1270. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. J Kennedy, K.-J. Lee, B. W McCrindle, and A. S Teebi Microcephaly-cardiomyopathy syndrome: confirmation of the phenotype J. Med. Genet., November 1, 1999; 36(11): 854 - 855. [Abstract] [Full Text]
|
|